This company listing is no longer active
De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!
Imagion Biosystems Inkomsten in het verleden
Verleden criteriumcontroles 0/6
Imagion Biosystems's earnings have been declining at an average annual rate of -12.6%, while the Medical Equipment industry saw earnings growing at 5.8% annually. Revenues have been growing at an average rate of 16.5% per year.
Belangrijke informatie
-12.6%
Groei van de winst
34.9%
Groei van de winst per aandeel
| Medical Equipment Groei van de industrie | 5.8% |
| Inkomstengroei | 16.5% |
| Rendement op eigen vermogen | n/a |
| Nettomarge | -335.6% |
| Laatste winstupdate | 30 Jun 2023 |
Recente prestatie-updates uit het verleden
Geen updates
Recent updates
Opbrengsten en kosten
Hoe Imagion Biosystems geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
| Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
|---|---|---|---|---|
| 30 Jun 23 | 3 | -12 | 9 | 0 |
| 31 Mar 23 | 3 | -11 | 9 | 0 |
| 31 Dec 22 | 3 | -10 | 8 | 0 |
| 30 Sep 22 | 2 | -10 | 7 | 0 |
| 30 Jun 22 | 0 | -10 | 6 | 0 |
| 31 Mar 22 | 2 | -8 | 6 | 0 |
| 31 Dec 21 | 3 | -6 | 6 | 0 |
| 30 Sep 21 | 3 | -6 | 6 | 0 |
| 30 Jun 21 | 3 | -5 | 6 | 0 |
| 31 Mar 21 | 3 | -5 | 5 | 0 |
| 31 Dec 20 | 3 | -5 | 5 | 0 |
| 30 Sep 20 | 3 | -5 | 4 | 0 |
| 30 Jun 20 | 2 | -4 | 4 | 0 |
| 31 Mar 20 | 2 | -4 | 4 | 0 |
| 31 Dec 19 | 2 | -3 | 3 | 0 |
| 30 Sep 19 | 2 | -4 | 4 | 0 |
| 30 Jun 19 | 2 | -5 | 5 | 0 |
| 31 Mar 19 | 1 | -7 | 5 | 0 |
| 31 Dec 18 | 0 | -8 | 6 | 0 |
| 30 Sep 18 | 0 | -8 | 6 | 1 |
| 30 Jun 18 | 0 | -8 | 6 | 1 |
| 31 Mar 18 | 0 | -8 | 5 | 2 |
| 31 Dec 17 | 0 | -8 | 5 | 2 |
| 31 Dec 16 | 0 | -12 | 1 | 6 |
| 31 Dec 15 | 0 | -4 | 0 | 4 |
| 31 Dec 14 | 0 | -3 | 0 | 2 |
Kwaliteitswinsten: IBXDA is currently unprofitable.
Groeiende winstmarge: IBXDA is currently unprofitable.
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: IBXDA is unprofitable, and losses have increased over the past 5 years at a rate of 12.6% per year.
Versnelling van de groei: Unable to compare IBXDA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Winst versus industrie: IBXDA is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (-3%).
Rendement op eigen vermogen
Hoge ROE: IBXDA's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.